Understanding the critical differences between regulated medications and unregulated supplements is essential for patients and clinicians considering weight management options
In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context
In June, Nestl Health Science launched GLP-1nutrition.com, providing comprehensive support for people taking GLP-1 medications for weight loss
Novo Nordisk: Top Legal Representatives Novo Nordisks top legal representative was from Japan-based Sonoda & Kobayashi, followed by Murayama Yasuhiko of Shiga International Patent Office
Real-World Insights Into Incretin-Based Therapy: Associations Between Changes in Taste Perception and Appetite Regulation in Individuals With Obesity and Overweight: A Cross-Sectional Study